Merit Medical Systems (MMSI) 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 05, 2014
Document Information [Abstract]	'	'
Entity Registrant Name	'MERIT MEDICAL SYSTEMS INC	'
Entity Central Index Key	'0000856982	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	43,402,718

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash and cash equivalents	$6,438	$7,459
Trade receivables — net of allowance for uncollectible accounts — 2014 — $920 and 2013 — $840	69,387	60,186
Employee receivables	181	224
Other receivables	4,221	3,279
Inventories	92,931	82,378
Prepaid expenses	5,687	5,121
Prepaid income taxes	1,199	1,232
Deferred income tax assets	5,626	5,638
Income tax refund receivables	315	398
Total current assets	185,985	165,915
PROPERTY AND EQUIPMENT:	'	'
Land and land improvements	16,948	16,240
Buildings	132,282	127,747
Manufacturing equipment	144,435	136,768
Furniture and fixtures	36,566	32,327
Leasehold improvements	15,159	13,692
Construction-in-progress	23,371	25,172
Total property and equipment	368,761	351,946
Less accumulated depreciation	-121,106	-108,676
Property and equipment — net	247,655	243,270
OTHER ASSETS:	'	'
Goodwill	184,505	184,505
Deferred income tax assets	799	800
Other assets	16,328	13,806
Total other assets	312,869	319,098
TOTAL	746,509	728,283
CURRENT LIABILITIES:	'	'
Trade payables	26,709	26,511
Accrued expenses	32,692	27,702
Current portion of long-term debt	10,000	10,000
Advances from employees	894	292
Income taxes payable	3,805	1,089
Total current liabilities	74,100	65,594
LONG-TERM DEBT	230,484	238,854
DEFERRED INCOME TAX LIABILITIES	2,335	2,548
LIABILITIES RELATED TO UNRECOGNIZED TAX BENEFITS	1,187	2,031
DEFERRED COMPENSATION PAYABLE	8,477	7,833
DEFERRED CREDITS	2,934	3,065
OTHER LONG-TERM OBLIGATIONS	2,741	2,652
Total liabilities	322,258	322,577
COMMITMENTS AND CONTINGENCIES (Notes 5, 9, 10 and 13)	'	'
STOCKHOLDERS’ EQUITY:	'	'
Preferred stock — 5,000 shares authorized as of September 30, 2014 and December 31, 2013; no shares issued	0	0
Common stock, no par value; 100,000 shares authorized; 43,239 and 42,846 shares issued at September 30, 2014 and December 31, 2013, respectively	182,614	177,775
Retained earnings	241,291	226,988
Accumulated other comprehensive income	346	943
Total stockholders’ equity	424,251	405,706
TOTAL	746,509	728,283
Developed technology — net of accumulated amortization — 2014 — $25,409 and 2013 — $17,602	'	'
OTHER ASSETS:	'	'
Intangible Assets	81,892	91,052
Other — net of accumulated amortization — 2014 — $21,361 and 2013 — $18,870	'	'
OTHER ASSETS:	'	'
Intangible Assets	$29,345	$28,935

CONSOLIDATED_BALANCE_SHEETS_CO

CONSOLIDATED BALANCE SHEETS CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
CURRENT ASSETS:	'	'
Trade receivables, allowances (in usd)	$920	$840
STOCKHOLDERS’ EQUITY:	'	'
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Common Stock, Par or Stated Value Per Share	'	'
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	43,239,000	42,846,000
Other	'	'
OTHER ASSETS:	'	'
Intangibles, accumulated amortization (in usd)	21,361	18,870
Developed technology	'	'
OTHER ASSETS:	'	'
Intangibles, accumulated amortization (in usd)	$25,409	$17,602

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
NET SALES	$128,808	$115,210	$376,909	$329,033
COST OF SALES	71,387	64,180	211,821	188,025
GROSS PROFIT	57,421	51,030	165,088	141,008
OPERATING EXPENSES:	'	'	'	'
Selling, general, and administrative	36,328	31,350	111,682	95,002
Research and development	8,688	7,308	27,109	25,064
Intangible assets impairment charge	1,102	8,089	1,102	8,089
Contingent consideration benefit	-773	-4,108	-754	-4,075
Total operating expenses	45,345	42,639	139,139	124,080
INCOME FROM OPERATIONS	12,076	8,391	25,949	16,928
OTHER INCOME (EXPENSE):	'	'	'	'
Interest income	41	69	187	200
Interest (expense)	-2,008	-1,916	-6,967	-5,297
Other income (expense) — net	144	-104	52	-174
Other (expense) — net	-1,823	-1,951	-6,728	-5,271
INCOME BEFORE INCOME TAXES	10,253	6,440	19,221	11,657
INCOME TAX EXPENSE	2,489	833	4,918	1,627
NET INCOME	$7,764	$5,607	$14,303	$10,030
EARNINGS PER COMMON SHARE:	'	'	'	'
Basic (in dollars per share)	$0.18	$0.13	$0.33	$0.24
Diluted (in dollars per share)	$0.18	$0.13	$0.33	$0.23
AVERAGE COMMON SHARES:	'	'	'	'
Basic (in shares)	43,229	42,596	43,053	42,560
Diluted (in shares)	43,398	42,872	43,315	42,793

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income	$7,764	$5,607	$14,303	$10,030
Other comprehensive income (loss):	'	'	'	'
Interest rate swap	794	-722	-66	2,533
Less income tax benefit (expense)	-308	281	26	-985
Foreign currency translation adjustment	-682	342	-739	253
Less income tax benefit (expense)	151	-8	182	8
Total other comprehensive income (loss)	-45	-107	-597	1,809
Total comprehensive income	$7,719	$5,500	$13,706	$11,839

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income	$14,303	$10,030
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	26,719	23,926
Losses on sales and/or abandonment of property and equipment	549	102
Write-off of patents and intangible assets	1,360	8,169
Amortization of deferred credits	-131	-97
Amortization of long-term debt issuance costs	741	598
Deferred income taxes	-184	-13
Excess tax benefits from stock-based compensation	-243	-145
Stock-based compensation expense	1,004	1,072
Changes in operating assets and liabilities, net of effects from acquisitions:	'	'
Trade receivables	-9,198	-3,700
Employee receivables	44	-78
Other receivables	-885	-435
Inventories	-10,553	3,161
Prepaid expenses	-608	-702
Prepaid income taxes	33	-17
Income tax refund receivables	10	527
Other assets	-1,128	-923
Trade payables	655	-4,078
Accrued expenses	4,686	-149
Advances from employees	599	164
Income taxes payable	3,248	-138
Liabilities related to unrecognized tax benefits	-844	-903
Deferred compensation payable	644	865
Other long-term obligations	764	-3,612
Total adjustments	17,282	23,594
Net cash provided by operating activities	31,585	33,624
Capital expenditures for:	'	'
Property and equipment	-24,262	-48,035
Intangible assets	-1,368	-1,143
Proceeds from sale-leaseback transaction	3,184	0
Proceeds from the sale of property and equipment	62	72
Cash paid in acquisitions, net of cash acquired	-4,202	-1,000
Net cash used in investing activities	-26,586	-50,106
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock	3,811	1,159
Proceeds from issuance of long-term debt	108,782	110,225
Payments on long-term debt	-117,772	-96,634
Proceeds from industrial assistant grants	0	900
Excess tax benefits from stock-based compensation	243	145
Contingent payments related to acquisitions	-55	-60
Payment of taxes related to an exchange of common stock	-220	-21
Net cash (used in) provided by financing activities	-5,211	15,714
EFFECT OF EXCHANGE RATES ON CASH	-809	164
NET DECREASE IN CASH AND CASH EQUIVALENTS	-1,021	-604
CASH AND CASH EQUIVALENTS:	'	'
Beginning of period	7,459	9,719
End of period	6,438	9,115
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	'	'
Interest (net of capitalized interest of $294 and $797, respectively)	7,204	5,381
Income taxes	2,679	2,024
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES	'	'
Property and equipment purchases in accounts payable	3,853	5,340
Merit common stock surrendered (108 and 45 shares, respectively) in exchange for exercise of stock options	$1,641	$452

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Statement of Cash Flows [Abstract]	'	'
Net capitalized interest	$294	$797
Company's common stock surrendered in exchange for the exercise of stock options (in shares)	108,000	45,000

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation. The interim consolidated financial statements of Merit Medical Systems, Inc. ("Merit," "we" or "us") for the three and nine months ended September 30, 2014 and 2013 are not audited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of our financial position as of September 30, 2014 and our results of operations and cash flows for the three and nine-month periods ended September 30, 2014 and 2013. The results of operations for the three and nine-month periods ended September 30, 2014 are not necessarily indicative of the results for a full-year period. These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission (the "SEC") on March 12, 2014 (the "2013 Form 10-K").

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories. Inventories are stated at the lower of cost or market. Inventories at September 30, 2014 and December 31, 2013, consisted of the following (in thousands):
		30-Sep-14		31-Dec-13
	Finished goods	$	50,439	$	43,364
	Work-in-process	11,927		6,222
	Raw materials	30,565		32,792
	Total	$	92,931	$	82,378

Stockbased_Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	Stock-Based Compensation. Stock-based compensation expense before income tax expense for the three and nine-month periods ended September 30, 2014 and 2013, consisted of the following (in thousands):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014		2013
	Cost of goods sold	$	19		$	18	109		$	98
	Research and development	24			20		57		69
	Selling, general, and administrative	298			251		838		905
	Stock-based compensation expense before taxes	$	341		$	289	$	1,004	$	1,072
	As of September 30, 2014, the total remaining unrecognized compensation cost related to non-vested stock options, net of expected forfeitures, was approximately $3.3 million and is expected to be recognized over a weighted average period of 3.0 years.
	During the three months ended September 30, 2014, we did not grant any stock-based awards. During the nine months ended September 30, 2014, we granted awards representing 125,000 shares of our common stock. During the three and nine months ended September 30, 2013, we granted awards representing 172,500 and 347,500 shares, respectively, of our common stock. We use the Black-Scholes methodology to value the stock-based compensation expense for options. In applying the Black-Scholes methodology to our outstanding option grants, we used the following assumptions:
		Nine Months Ended
		September 30,		September 30,
		2014		2013
	Risk-free interest rate	1.97%		0.65% - 1.16%
	Expected option life	5.5 years		4.2 - 6.0 years
	Expected dividend yield	—%		—%
	Expected price volatility	36.90%		34.08% - 41.67%
	For purposes of the foregoing analysis, the average risk-free interest rate is determined using the U.S. Treasury rate in effect as of the date of grant, based on the expected term of the stock option. The expected term of the stock options is determined using the historical exercise behavior of employees. The expected price volatility is determined using a weighted average of daily historical volatility of our stock price over the corresponding expected option life and implied volatility based on recent trends of the daily historical volatility. For options with a vesting period, compensation expense is recognized on a straight-line basis over the service period, which corresponds to the vesting period.

Earnings_Per_Common_Share_EPS

Earnings Per Common Share (EPS)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
Earnings Per Common Share (EPS)	'
	Earnings Per Common Share (EPS). The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the following periods consisted of the following (in thousands, except per share amounts):
		Three Months					Nine Months
		Net		Shares	Per Share		Net		Shares	Per Share
		Income			Amount		Income			Amount
	Period ended September 30, 2014
	Basic EPS	$	7,764	43,229	$0.18		$	14,303	43,053	$0.33
	Effect of dilutive stock options and warrants			169					262
	Diluted EPS	$	7,764	43,398	$0.18		$	14,303	43,315	$0.33
	Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive			1,173					1,427
	Period ended September 30, 2013
	Basic EPS	$	5,607	42,596	$	0.13	$	10,030	42,560	$	0.24
	Effect of dilutive stock options and warrants			276					233
	Diluted EPS	$	5,607	42,872	$	0.13	$	10,030	42,793	$	0.23
	Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive			1,857					2,125

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions. On August 8, 2014, we entered into a license agreement and a distribution agreement with a medical device company for the right to manufacture and sell certain percutaneous transluminal angioplasty balloon catheter products. As of September 30, 2014, we had paid $2.0 million in connection with these two agreements. We are obligated to pay an additional $5.0 million if certain milestones set forth in the license agreement are reached. We accounted for the transaction as an asset purchase. Of the purchase price paid as of September 30, 2014, $200,000 was allocated to a distribution agreement asset, which we intend to amortize over a period of 5 years, and $1.8 million was allocated to a license agreement asset, which we intend to amortize over a period of 10 years.
	On July 15, 2014, we entered into a purchase agreement to acquire certain assets from a limited liability company. In connection with this agreement, we paid approximately $752,000. The primary assets acquired from this entity were manufacturing and export licenses. We accounted for the transaction as an asset purchase. We recorded the amount paid on the closing date as a license agreement asset, which we intend to amortize over a period of 10 years.
	On May 8, 2014, we purchased 737,628 shares of the common stock of G Medix, Inc., a Minnesota corporation ("G Medix"), for an aggregate price of approximately $1.8 million. Our purchase of the G Medix shares, which represents an ownership interest in G Medix of approximately 19%, has been accounted for at cost. We made a refundable advance to G Medix of $350,000 in 2013 that was credited against the final purchase amount, resulting in $1.45 million of cash purchase price paid to G Medix during 2014. G Medix develops catheter-based therapeutic devices.
	On October 4, 2013, we acquired certain assets contemplated by an Asset Purchase Agreement we executed with Datascope Corp. ("Datascope"), a Delaware corporation. The primary assets we acquired consist of the Safeguard® Pressure Assisted Device, which assists in obtaining and maintaining hemostasis after a femoral procedure, and the Air-Band™ Radial Compression Device, which is indicated to assist hemostasis of the radial artery puncture site while maintaining visibility. We accounted for this acquisition as a business combination. We made a payment of approximately $27.5 million to acquire these assets. Acquisition-related costs during the year ended December 31, 2013, which were included in selling, general, and administrative expenses in the consolidated statements of income included in our 2013 Form 10-K, were not material. The results of operations related to the Datascope acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2013, our net sales of Datascope products were approximately $1.6 million. It is not practical to separately report the earnings related to the Datascope acquisition, as we do not split out sales costs related to Datascope products, principally because our sales representatives sell multiple products (including Datascope products) in the cardiovascular business segment. The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	478
	Intangibles
	Developed technology	18,200
	Customer lists	390
	Trademarks	320
	Goodwill	8,112
	Total assets acquired	$	27,500
	With respect to the Datascope assets, we are amortizing developed technology over ten years and customer lists on an accelerated basis over six years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is ten years.
	On October 4, 2013, we acquired certain assets contemplated by an Asset Purchase Agreement with Radial Assist, LLC ("Radial Assist"), a Georgia limited liability company. The primary assets we acquired consist of the Rad Board®, Rad Board®Xtra™, Rad Trac™, and Rad Rest® devices. The Rad Board is designed to provide a larger work space for physicians and an area for patients to rest their arms during radial procedures. The Rad Board Xtra is designed to work in conjunction with the Rad Board by extending the usable work space and allowing for a 90-degree perpendicular extension of the arm for physicians who prefer doing procedures at a 90-degree angle. The Rad Trac is also designed to be used with the Rad Board and facilitates placement and removal of the Rad Board with the patient still on the table. The Rad Rest is a disposable, single-use product designed to stabilize the arm by ergonomically supporting the elbow, forearm and wrist during radial procedures. We accounted for this acquisition as a business combination. We made a payment of approximately $2.5 million to acquire these assets. Acquisition-related costs during the year ended December 31, 2013, which were included in selling, general, and administrative expenses in the consolidated statements of income included in the 2013 Form 10-K, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2013, our net sales of Radial Assist products were approximately $191,000. It is not practical to separately report the earnings related to the Radial Assist acquisition, as we cannot split out sales costs related to Radial Assist products, principally because our sales representatives are selling multiple products (including Radial Assist products) in the cardiovascular business segment. The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	16
	Intangibles
	Developed technology	1,520
	Customer lists	20
	Trademarks	40
	Goodwill	904
	Total assets acquired	$	2,500
	With respect to the Radial Assist assets, we are amortizing developed technology over ten years and customer lists on an accelerated basis over six years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 10.07 years.
	In connection with our Datascope and Radial Assist acquisitions, we paid approximately $798,000 in long-term debt issuance costs to Wells Fargo Bank related to the amendment of our Credit Agreement (see Note 9). These costs consisted primarily of loan origination fees that we intend to amortize over the remaining contract term of our Credit Agreement, which matures on December 19, 2017.
	The following table summarizes our unaudited consolidated results of operations for the three and nine-month periods ended September 30, 2013, as well as unaudited pro forma consolidated results of operations as though the Datascope acquisition had occurred on January 1, 2013 (in thousands, except per common share amounts):
		Three Months Ended				Nine Months Ended
		30-Sep-13				30-Sep-13
		As Reported		Pro Forma		As Reported		Pro Forma
	Net sales	$	115,210	$	116,971	$	329,033	$	334,317
	Net income	5,607		5,788		10,030		10,572
	Earnings per common share:
	Basic	$	0.13	$	0.14	$	0.24	$	0.25
	Diluted	$	0.13	$	0.14	$	0.23	$	0.25
	The unaudited pro forma information set forth above is for informational purposes only and includes adjustments for amortization expense related to acquired intangible assets and interest expense on long-term debt. The pro forma information should not be considered indicative of actual results that would have been achieved if the Datascope acquisition had occurred on January 1, 2013, or results that may be obtained in any future period. The pro forma consolidated results of operations do not include the pro forma effect of the Radial Assist acquisition, as we do not deem the pro forma effect of the Radial Assist transaction to be material.
	The goodwill arising from the acquisitions discussed above consists largely of the synergies and economies of scale we expect to achieve from combining the acquired assets and operations with our historical operations (see Note 12). The goodwill recognized from these acquisitions is expected to be deductible for income tax purposes.

Segment_Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting	'
	Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology medical device products which assist in diagnosing and treating coronary artery disease, peripheral vascular disease and other non-vascular diseases and includes embolization devices and the CRM/EP devices we acquired through our acquisition of Thomas Medical Products, Inc. Our endoscopy segment consists of gastroenterology and pulmonology medical device products which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on operating income. Financial information relating to our reportable operating segments and reconciliations to the consolidated totals is as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Revenues
	Cardiovascular	$	124,191	$	110,859	363,767		$	316,566
	Endoscopy	4,617		4,351		13,142		12,467
	Total Revenues	128,808		115,210		376,909		329,033
	Operating income
	Cardiovascular	11,520		7,753		25,216		16,031
	Endoscopy	556		638		733		897
	Total operating income	$	12,076	$	8,391	$	25,949	$	16,928

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements (Notes)	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements. In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2014-15, which requires management to assess, at each annual and interim reporting period, the entity's ability to continue as a going concern within one year after the date that the financial statements are issued and provide related disclosures. The guidance is effective for the year ended December 31, 2016, with early adoption permitted. We have assessed the impact of this standard and do not believe that it will have a material impact on our consolidated financial statements or disclosures upon adoption.
	In May 2014, the FASB issued authoritative guidance amending the FASB Accounting Standards Codification and creating a new Topic 606, Revenue from Contracts with Customers. The new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP applicable to revenue transactions. This guidance provides that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The existing industry guidance will be eliminated when the new guidance becomes effective and annual disclosures will be substantially revised. The amendments in the new guidance are effective for annual reporting periods beginning after December 15, 2016, including interim periods within those reporting periods. Early application is not permitted. We intend to adopt the new standard effective January 1, 2017. This update provides for two transition methods to the new guidance: a full retrospective or a modified retrospective adoption. We are evaluating the transition methods and the anticipated impact the application of this guidance will have on our financial position, results of operations and cash flows.
	In July 2013, the FASB issued authoritative guidance which concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carry-forward, a similar tax loss, or a tax credit carry-forward. We adopted this guidance early, as permitted, for the fiscal year ended December 31, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes. Our overall effective tax rate for the three months ended September 30, 2014 was 24.3% compared to 12.9% for the corresponding period of 2013. For the nine months ended September 30, 2014, our overall effective tax rate was 25.6%, compared to 14.0% for the corresponding period of 2013. The increase in the effective tax rate for the three and nine-month periods ended September 30, 2014 was primarily attributable to the increase in income before income taxes, resulting in a relatively lower impact of certain discrete tax benefits during the three and nine-month periods ended September 30, 2014 compared to the corresponding periods of 2013. Additionally, the effective income tax rates for the three and nine month periods ended September 30, 2014, compared to the corresponding periods of 2013, were higher as a result of a higher mix of earnings from our U.S. operations, which are taxed at a higher rate than our foreign operations.

Longterm_Debt

Long-term Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Long-term Debt	'
	Long-term Debt. We entered into an Amended and Restated Credit Agreement, dated December 19, 2012, with the lenders who are or may become party thereto (collectively, the "Lenders") and Wells Fargo Bank, National Association ("Wells Fargo"), as administrative agent for the Lenders, which was amended on October 4, 2013 by a First Amendment to the Amended and Restated Credit Agreement by and among Merit, certain subsidiaries of Merit, the Lenders and Wells Fargo as administrative agent for the Lenders (as amended, the "Credit Agreement"). Pursuant to the terms of the Credit Agreement, the Lenders have agreed to make revolving credit loans up to an aggregate amount of $215 million. The Lenders also made a term loan in the amount of $100 million, repayable in quarterly installments in the amounts provided in the Credit Agreement until the maturity date of December 19, 2017, at which time the term and revolving credit loans, together with accrued interest thereon, will be due and payable. In addition, certain mandatory prepayments are required to be made upon the occurrence of certain events described in the Credit Agreement. Wells Fargo has agreed, upon satisfaction of certain conditions, to make swingline loans from time to time through the maturity date in amounts equal to the difference between the amounts actually loaned by the Lenders and the aggregate revolving credit commitment. The Credit Agreement is collateralized by substantially all of our assets. At any time prior to the maturity date, we may repay any amounts owing under our term loan, all revolving credit loans, and all swingline loans in whole or in part, subject to certain minimum thresholds, without premium or penalty, other than breakage costs. As of September 30, 2014, Wells Fargo was the sole Lender under the Credit Agreement.
	The term loan and any revolving credit loans made under the Credit Agreement bear interest, at our election, at either (i) the base rate (described below) plus 0.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1), (ii) the London Inter-Bank Offered Rate (“LIBOR”) Market Index Rate (as defined in the Credit Agreement) plus 1.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1), or (iii) the LIBOR Rate (as defined in the Credit Agreement) plus 1.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1). Initially, the term loan and revolving credit loans under the Credit Agreement bore interest, at our election, at either (x) the base rate plus 1.00%, (y) the LIBOR Market Index Rate, plus 2.00%, or (z) the LIBOR Rate plus 2.00%. Swingline loans bear interest at the LIBOR Market Index Rate plus 1.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1). Initially, swingline loans bore interest at the LIBOR Market Index Rate plus 2.00%. Interest on each loan featuring the base rate or the LIBOR Market Index Rate is due and payable on the last business day of each calendar month; interest on each loan featuring the LIBOR Rate is due and payable on the last day of each interest period selected by us when selecting the LIBOR Rate as the benchmark for interest calculation. For purposes of the Credit Agreement, the base rate means the highest of (i) the prime rate (as announced by Wells Fargo), (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%. Our obligations under the Credit Agreement and all loans made thereunder are fully secured by a security interest in our assets pursuant to a separate collateral agreement entered into in conjunction with the Credit Agreement.
	The Credit Agreement contains covenants, representations and warranties and other terms customary for revolving credit loans of this nature. In this regard, the Credit Agreement requires us to not, among other things, (a) permit the Consolidated Total Leverage Ratio (as defined in the Credit Agreement) to be greater than 4.75 to 1 through the end of 2013, no more than 4.00 to 1 as of the fiscal quarter ending March 31, 2014, no more than 3.75 to 1 as of the fiscal quarter ending June 30, 2014, no more than 3.50 to 1 as of the fiscal quarter ending September 30, 2014, no more than 3.25 to 1 as of the fiscal quarter ending December 31, 2014, no more than 3.00 to 1 as of any fiscal quarter ending during 2015, no more than 2.75 to 1 as of any fiscal quarter ending during 2016, and no more than 2.50 to 1 as of any fiscal quarter ending thereafter; (b) for any period of four consecutive fiscal quarters, permit the ratio of Consolidated EBITDA (as defined in the Credit Agreement and subject to certain adjustments) to Consolidated Fixed Charges (as defined in the Credit Agreement) to be less than 1.75 to 1; (c) subject to certain adjustments, permit Consolidated Net Income (as defined in the Credit Agreement) for certain periods to be less than $0; or (d) subject to certain conditions and adjustments, permit the aggregate amount of all Facility Capital Expenditures (as defined in the Credit Agreement) in any fiscal year beginning in 2013 to exceed $30 million. Additionally, the Credit Agreement contains various negative covenants with which we must comply, including, but not limited to, limitations respecting: the incurrence of indebtedness, the creation of liens or pledges on our assets, mergers or similar combinations or liquidations, asset dispositions, the repurchase or redemption of equity interests or debt, the issuance of equity, the payment of dividends and certain distributions, the entry into related party transactions and other provisions customary in similar types of agreements. As of September 30, 2014, we were in compliance with all covenants set forth in the Credit Agreement.
	We had originally entered into an unsecured credit agreement, dated September 30, 2010, with certain lenders who were or became party thereto and Wells Fargo, as administrative agent for the lenders. Pursuant to the terms of that credit agreement, the lenders agreed to make revolving credit loans up to an aggregate amount of $125 million. Wells Fargo also agreed to make swingline loans from time to time through the maturity date of September 10, 2015 in amounts equal to the difference between the amount actually loaned by the Lenders and the aggregate credit agreement. The unsecured credit agreement was amended and restated as of December 19, 2012, as the Credit Agreement.
	In summary, principal balances under our long-term debt as of September 30, 2014 and December 31, 2013, consisted of the following (in thousands):
		30-Sep-14			31-Dec-13
	Term loan	$	85,000		$	92,500
	Revolving credit loans	155,484			156,354
	Total long-term debt	240,484			248,854
	Less current portion	10,000			10,000
	Long-term portion	$	230,484		$	238,854
	Future minimum principal payments on our long-term debt as of September 30, 2014, were as follows (in thousands):
	Years Ending		Future Minimum
	December 31		Principal Payments
	2014		$	2,500
	2015		10,000
	2016		10,000
	2017		217,984
	Total future minimum principal payments		$	240,484
	As of September 30, 2014, we had outstanding borrowings of approximately $240.5 million under the Credit Agreement, with available borrowings of approximately $19.1 million, based on the leverage ratio in the terms of the Credit Agreement. Our interest rate as of September 30, 2014 was a fixed rate of 3.23% on $141.3 million as a result of an interest rate swap (see Note 10), a variable floating rate of 2.41% on $39.7 million and a variable floating rate of 2.49% on approximately $59.5 million. Our interest rate as of December 31, 2013 was a fixed rate of 4.23% on $145.0 million as a result of an interest rate swap, variable floating rate of 3.42% on $101.5 million and a variable floating rate of 3.50% on approximately $2.4 million.

Derivatives

Derivatives	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives	'
	Derivatives.
	Interest Rate Swap. On December 19, 2012, we entered into a pay-fixed, receive-variable interest rate swap having an initial notional amount of $150 million with Wells Fargo to fix the one-month LIBOR rate at 0.98%. The variable portion of the interest rate swap is tied to the one-month LIBOR rate (the benchmark interest rate). On a monthly basis, under both the interest rate swap and the underlying debt, the interest rate is reset, the swap is settled with the counterparty and interest is paid. The notional amount of the interest rate swap is reduced quarterly by 50% of the minimum principal payment due under the terms of the Credit Agreement. The interest rate swap is scheduled to expire on December 19, 2017.
	As of September 30, 2014, our interest rate swap qualified as a cash flow hedge. The fair value of our interest rate swap at September 30, 2014 was an asset of approximately $1,137,000, which was offset by approximately $442,000 in deferred taxes. During the three and nine-month periods ended September 30, 2014, the amount reclassified from accumulated other comprehensive income to earnings due to hedge effectiveness was included in interest expense in the accompanying consolidated statements of income and was not material.
	Foreign Currency Forward Contracts. On August 29, 2014, we forecasted a net foreign currency exposure for September 30, 2014 (representing GBP-denominated receivables and Euro-denominated payables) of approximately 1,218,000 Euros and 741,000 GBPs. In order to partially offset such risks, at August 29, 2014 we entered into a 30-day forward contract for the Euro and GBP with a notional amount of approximately 1,218,000 Euros and notional amount of 741,000 GBPs. We enter into similar transactions at various times during the year to partially offset exchange rate risks we bear throughout the year. These contracts are marked to market at the end of each month. The effect on our consolidated statements of income for the three and nine-month periods ended September 30, 2014 and 2013 of all forward contracts, and the fair value of our open positions as of September 30, 2014, were not material.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements. Our financial assets carried at fair value measured on a recurring basis as of September 30, 2014 and December 31, 2013, consisted of the following (in thousands):
						Fair Value Measurements Using
			Total Fair			Quoted prices in				Significant other			Significant
			Value at			active markets				observable inputs			unobservable inputs
	Description		30-Sep-14			(Level 1)				(Level 2)			(Level 3)
	Interest rate swap (1)		$	1,137		$	—			$	1,137		$	—
						Fair Value Measurements Using
			Total Fair			Quoted prices in				Significant other			Significant
			Value at			active markets				observable inputs			unobservable inputs
	Description		31-Dec-13			(Level 1)				(Level 2)			(Level 3)
	Interest rate swap (1)		$	1,203		$	—			$	1,203		$	—
	(1)    The fair value of the interest rate swap is determined based on forward yield curves.
	Certain of our business combinations involve the potential for the payment of future contingent consideration, generally based on a percentage of future product sales or upon attaining specified future revenue milestones. The contingent consideration liability is re-measured at the estimated fair value at each reporting period with the change in fair value recognized as contingent consideration benefit in the accompanying consolidated statements of income. We measure the initial liability and re-measure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. Changes in the fair value of our contingent consideration liability during the three and nine-month periods ended September 30, 2014 and 2013, were as follows (in thousands):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2014			2013				2014			2013
	Beginning balance	$	2,507		$	6,692			$	2,526		$	6,697
	Fair value adjustments recorded to expense during the period	(773		)	(4,108		)		(754		)	(4,075		)
	Contingent payments made	(17		)	(22		)		(55		)	(60		)
	Ending balance	$	1,717		$	2,562			$	1,717		$	2,562
	The recurring Level 3 measurement of our contingent consideration liability includes the following significant unobservable inputs at September 30, 2014 (in thousands):
	Contingent consideration liability		Fair value at September 30, 2014			Valuation technique		Unobservable inputs		Range
	Revenue-based payments		$	1,462		Discounted cash flow		Discount rate		1% - 14%
								Probability of milestone payment		90%
								Projected year of payments		2014-2028
	Other payments		$	255		Discounted cash flow		Discount rate		5%
								Probability of milestone payment		100%
								Projected year of payments		2015-2016
	The contingent consideration liability is re-measured to fair value each reporting period using projected revenues, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. A decrease in the probability of any milestone payment may result in lower fair value measurements. An increase (decrease) in either the discount rate or the time to payment, in isolation, may result in a significantly lower (higher) fair value measurement.
	Our determination of the fair value of the contingent consideration liability could change in future periods based upon our ongoing evaluation of these significant unobservable inputs. We intend to record any such change in fair value to selling, general, and administrative expenses in our consolidated statements of income. As of September 30, 2014, approximately $1.4 million was included in other long-term obligations and $365,000 was included in accrued expenses in our consolidated balance sheet. As of December 31, 2013, approximately $2.3 million was included in other long-term obligations and $274,000 was included in accrued expenses in our consolidated balance sheet. The cash paid to settle the contingent consideration liability recognized at fair value as of the acquisition date (including measurement-period adjustments) has been reflected as a cash outflow from financing activities in the accompanying consolidated statements of cash flows. See Note 12 for further information regarding the $874,000 of fair value reductions to the contingent consideration liability we incurred in connection with our acquisition of the Ostial assets and the associated intangible asset impairment charge.
	During the three and nine-month periods ended September 30, 2014, we had losses of approximately $1.2 million and $1.4 million, respectively, compared to $8.1 million and $8.2 million for the corresponding three and nine-month periods ended September 30, 2013, respectively, related to the measurement of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.
	Of the loss amount noted in the preceding paragraph for the three and nine-month periods ended September 30, 2014, approximately $1.1 million related to the impairment of our intangible assets related to our Ostial acquisition (see Note 12). The non-recurring fair values of the Ostial intangible assets as of September 30, 2014 were approximately $447,000 for developed technology. Determining the fair value is judgmental in nature and requires the use of significant estimates and assumptions, which are considered to be Level 3 inputs. These values were determined using a discounted cash flow valuation technique. We did not have other intangible assets measured at fair value on a non-recurring basis as of September 30, 2014.
	The carrying amount of cash and cash equivalents, receivables, and trade payables approximates fair value because of the immediate, short-term maturity of these financial instruments. The carrying amount of long-term debt approximates fair value, as determined by borrowing rates estimated to be available to us for debt with similar terms and conditions. The fair value of assets and liabilities whose carrying value approximates fair value is determined using Level 2 inputs, with the exception of cash and cash equivalents, which are valued using Level 1 inputs.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets. Other intangible assets as of September 30, 2014 and December 31, 2013, consisted of the following (in thousands):
		30-Sep-14
		Gross Carrying		Accumulated			Net Carrying
		Amount		Amortization			Amount
	Patents	$	9,921	$	(2,104	)	$	7,817
	Distribution agreements	5,376		(2,139		)	3,237
	License agreements	6,327		(1,664		)	4,663
	Trademarks	7,313		(1,961		)	5,352
	Covenants not to compete	1,029		(577		)	452
	Customer lists	20,473		(12,649		)	7,824
	Royalty agreements	267		(267		)	—
	Total	$	50,706	$	(21,361	)	$	29,345
		December 31, 2013
		Gross Carrying		Accumulated			Net Carrying
		Amount		Amortization			Amount
	Patents	$	9,302	$	(2,374	)	$	6,928
	Distribution agreements	5,176		(1,780		)	3,396
	License agreements	3,783		(1,249		)	2,534
	Trademarks	7,622		(1,844		)	5,778
	Covenants not to compete	1,029		(399		)	630
	Customer lists	20,626		(10,957		)	9,669
	Royalty agreements	267		(267		)	—
	Total	$	47,805	$	(18,870	)	$	28,935
	Aggregate amortization expense related to developed technology and other intangible assets for the three and nine-month periods ended September 30, 2014 was approximately $3.8 million and $11.2 million, respectively, and approximately $3.4 million and $10.4 million for the three and nine-month periods ending September 30, 2013, respectively.
	Estimated amortization expense for developed technology and other intangible assets for the next five years consists of the following as of September 30, 2014 (in thousands):
	Year Ending December 31
	Remaining 2014	$	3,821
	2015	15,031
	2016	14,303
	2017	13,898
	2018	13,369
	We evaluate long-lived assets, including amortizing intangible assets, for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We perform the impairment analysis at the asset group for which the lowest level of identifiable cash flows are largely independent of the cash flows of other assets and liabilities. We compared the carrying value of the amortizing intangible assets acquired in our Ostial acquisition to the undiscounted cash flows expected to result from our operation of the Ostial asset group, and we determined that the carrying amount was not recoverable. We then determined the fair value of the amortizing assets related to the Ostial acquisition based on estimated future cash flows discounted back to their present value using a discount rate that reflects the risk profiles of the underlying activities. Some of the factors that influenced our estimated cash flows were slower than anticipated sales growth in the products acquired from our Ostial acquisition and uncertainty about future sales growth. The excess of the carrying value compared to the fair value was recognized as an intangible asset impairment charge. During the three months ended September 30, 2014, we recorded an impairment charge of approximately $1.1 million, which was offset by approximately $874,000 of fair value reductions to the contingent consideration liability. During the three months ended September 30, 2013, we recorded an impairment charge of approximately $8.1 million, which was offset by approximately $3.8 million of fair value reductions to the contingent consideration liability.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies. In the ordinary course of business, we are involved in various claims and litigation matters. These claims and litigation matters may include actions involving product liability, intellectual property, contractual disputes and employment matters. We do not believe that any such actions are likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs for these matters such as outside counsel fees and expenses are charged to expense in the period incurred.
	On April 4, 2013, we filed suit against Bard Access Systems, Inc. ("Bard") in the Third Judicial District Court for Salt Lake County, Utah, seeking a determination that Bard had breached a Purchasing Agreement we entered into with Specialized Health Products, Inc., which was subsequently acquired by Bard. On October 30, 2014, we settled the dispute and dismissed all claims with prejudice. Under the terms of the settlement agreement, Bard Access Systems granted Merit a non-exclusive, worldwide license to manufacture and distribute the SecureLoc® Safety Introducer Needle under our own trademark, and a covenant not to sue us for the term of all patents covering the SecureLoc®.
	Intellectual property rights, particularly patents, play a significant role in product development and help differentiate competitors in the medical device market. Competing companies may file infringement lawsuits in attempts to bolster their intellectual property portfolios or enhance their financial standing. Intellectual property litigation is time consuming, costly and unpredictable. Monetary judgments, remedies or restitution are often not determined until the conclusion of trial court proceedings, which can be modified on appeal. Accordingly, the outcomes of pending litigation are difficult to predict or quantify.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventories at September 30, 2014 and December 31, 2013, consisted of the following (in thousands):
		30-Sep-14		31-Dec-13
	Finished goods	$	50,439	$	43,364
	Work-in-process	11,927		6,222
	Raw materials	30,565		32,792
	Total	$	92,931	$	82,378

Stockbased_Compensation_Tables

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	'
	Stock-based compensation expense before income tax expense for the three and nine-month periods ended September 30, 2014 and 2013, consisted of the following (in thousands):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014		2013
	Cost of goods sold	$	19		$	18	109		$	98
	Research and development	24			20		57		69
	Selling, general, and administrative	298			251		838		905
	Stock-based compensation expense before taxes	$	341		$	289	$	1,004	$	1,072
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	'
	In applying the Black-Scholes methodology to our outstanding option grants, we used the following assumptions:
		Nine Months Ended
		September 30,		September 30,
		2014		2013
	Risk-free interest rate	1.97%		0.65% - 1.16%
	Expected option life	5.5 years		4.2 - 6.0 years
	Expected dividend yield	—%		—%
	Expected price volatility	36.90%		34.08% - 41.67%

Earnings_Per_Common_Share_EPS_

Earnings Per Common Share (EPS) (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the following periods consisted of the following (in thousands, except per share amounts):
		Three Months					Nine Months
		Net		Shares	Per Share		Net		Shares	Per Share
		Income			Amount		Income			Amount
	Period ended September 30, 2014
	Basic EPS	$	7,764	43,229	$0.18		$	14,303	43,053	$0.33
	Effect of dilutive stock options and warrants			169					262
	Diluted EPS	$	7,764	43,398	$0.18		$	14,303	43,315	$0.33
	Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive			1,173					1,427
	Period ended September 30, 2013
	Basic EPS	$	5,607	42,596	$	0.13	$	10,030	42,560	$	0.24
	Effect of dilutive stock options and warrants			276					233
	Diluted EPS	$	5,607	42,872	$	0.13	$	10,030	42,793	$	0.23
	Stock options excluded from the calculation of common stock equivalents as the impact was anti-dilutive			1,857					2,125

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2014
Datascope	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	478
	Intangibles
	Developed technology	18,200
	Customer lists	390
	Trademarks	320
	Goodwill	8,112
	Total assets acquired	$	27,500
Business Acquisition, Pro Forma Information	'
	The following table summarizes our unaudited consolidated results of operations for the three and nine-month periods ended September 30, 2013, as well as unaudited pro forma consolidated results of operations as though the Datascope acquisition had occurred on January 1, 2013 (in thousands, except per common share amounts):
		Three Months Ended				Nine Months Ended
		30-Sep-13				30-Sep-13
		As Reported		Pro Forma		As Reported		Pro Forma
	Net sales	$	115,210	$	116,971	$	329,033	$	334,317
	Net income	5,607		5,788		10,030		10,572
	Earnings per common share:
	Basic	$	0.13	$	0.14	$	0.24	$	0.25
	Diluted	$	0.13	$	0.14	$	0.23	$	0.25
Radial Assist	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	16
	Intangibles
	Developed technology	1,520
	Customer lists	20
	Trademarks	40
	Goodwill	904
	Total assets acquired	$	2,500

Segment_Reporting_Tables

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment	'
	Financial information relating to our reportable operating segments and reconciliations to the consolidated totals is as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Revenues
	Cardiovascular	$	124,191	$	110,859	363,767		$	316,566
	Endoscopy	4,617		4,351		13,142		12,467
	Total Revenues	128,808		115,210		376,909		329,033
	Operating income
	Cardiovascular	11,520		7,753		25,216		16,031
	Endoscopy	556		638		733		897
	Total operating income	$	12,076	$	8,391	$	25,949	$	16,928

Longterm_Debt_Tables

Long-term Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt Instruments	'
	In summary, principal balances under our long-term debt as of September 30, 2014 and December 31, 2013, consisted of the following (in thousands):
		30-Sep-14			31-Dec-13
	Term loan	$	85,000		$	92,500
	Revolving credit loans	155,484			156,354
	Total long-term debt	240,484			248,854
	Less current portion	10,000			10,000
	Long-term portion	$	230,484		$	238,854
Schedule of Maturities of Long-term Debt	'
	Future minimum principal payments on our long-term debt as of September 30, 2014, were as follows (in thousands):
	Years Ending		Future Minimum
	December 31		Principal Payments
	2014		$	2,500
	2015		10,000
	2016		10,000
	2017		217,984
	Total future minimum principal payments		$	240,484

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	'
	Our financial assets carried at fair value measured on a recurring basis as of September 30, 2014 and December 31, 2013, consisted of the following (in thousands):
						Fair Value Measurements Using
			Total Fair			Quoted prices in				Significant other			Significant
			Value at			active markets				observable inputs			unobservable inputs
	Description		30-Sep-14			(Level 1)				(Level 2)			(Level 3)
	Interest rate swap (1)		$	1,137		$	—			$	1,137		$	—
						Fair Value Measurements Using
			Total Fair			Quoted prices in				Significant other			Significant
			Value at			active markets				observable inputs			unobservable inputs
	Description		31-Dec-13			(Level 1)				(Level 2)			(Level 3)
	Interest rate swap (1)		$	1,203		$	—			$	1,203		$	—
	(1)    The fair value of the interest rate swap is determined based on forward yield curves.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	'
	Changes in the fair value of our contingent consideration liability during the three and nine-month periods ended September 30, 2014 and 2013, were as follows (in thousands):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2014			2013				2014			2013
	Beginning balance	$	2,507		$	6,692			$	2,526		$	6,697
	Fair value adjustments recorded to expense during the period	(773		)	(4,108		)		(754		)	(4,075		)
	Contingent payments made	(17		)	(22		)		(55		)	(60		)
	Ending balance	$	1,717		$	2,562			$	1,717		$	2,562
Fair Value Inputs, Liabilities, Quantitative Information	'
	The recurring Level 3 measurement of our contingent consideration liability includes the following significant unobservable inputs at September 30, 2014 (in thousands):
	Contingent consideration liability		Fair value at September 30, 2014			Valuation technique		Unobservable inputs		Range
	Revenue-based payments		$	1,462		Discounted cash flow		Discount rate		1% - 14%
								Probability of milestone payment		90%
								Projected year of payments		2014-2028
	Other payments		$	255		Discounted cash flow		Discount rate		5%
								Probability of milestone payment		100%
								Projected year of payments		2015-2016

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Other intangible assets	'
	Other intangible assets as of September 30, 2014 and December 31, 2013, consisted of the following (in thousands):
		30-Sep-14
		Gross Carrying		Accumulated			Net Carrying
		Amount		Amortization			Amount
	Patents	$	9,921	$	(2,104	)	$	7,817
	Distribution agreements	5,376		(2,139		)	3,237
	License agreements	6,327		(1,664		)	4,663
	Trademarks	7,313		(1,961		)	5,352
	Covenants not to compete	1,029		(577		)	452
	Customer lists	20,473		(12,649		)	7,824
	Royalty agreements	267		(267		)	—
	Total	$	50,706	$	(21,361	)	$	29,345
		December 31, 2013
		Gross Carrying		Accumulated			Net Carrying
		Amount		Amortization			Amount
	Patents	$	9,302	$	(2,374	)	$	6,928
	Distribution agreements	5,176		(1,780		)	3,396
	License agreements	3,783		(1,249		)	2,534
	Trademarks	7,622		(1,844		)	5,778
	Covenants not to compete	1,029		(399		)	630
	Customer lists	20,626		(10,957		)	9,669
	Royalty agreements	267		(267		)	—
	Total	$	47,805	$	(18,870	)	$	28,935
Estimated amortization expense	'
	Estimated amortization expense for developed technology and other intangible assets for the next five years consists of the following as of September 30, 2014 (in thousands):
	Year Ending December 31
	Remaining 2014	$	3,821
	2015	15,031
	2016	14,303
	2017	13,898
	2018	13,369

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Finished goods	$50,439	$43,364
Work-in-process	11,927	6,222
Raw materials	30,565	32,792
Total	$92,931	$82,378

Stockbased_Compensation_Alloca

Stock-based Compensation - Allocation of Recognized Period Costs (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$341	$289	$1,004	$1,072
Cost of goods sold	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	19	18	109	98
Research and development	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	24	20	57	69
Selling, general, and administrative	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated Share-based Compensation Expense	$298	$251	$838	$905

Stockbased_Compensation_Fair_V

Stock-based Compensation - Fair Value Calculation Assumptions (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Risk-free interest rate, minimum	1.97%	0.65%
Risk-free interest rate, maximum	'	1.16%
Expected option life	'5 years 6 months	'
Expected dividend yield	0.00%	0.00%
Expected price volatility, minimum	36.90%	34.08%
Expected price volatility, maximum	'	41.67%
Minimum	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected option life	'	'4 years 2 months 12 days
Maximum	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected option life	'	'6 years

Stockbased_Compensation_Stockb

Stock-based Compensation - Stock-based Compensation (Narrative) (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	'	$3.30	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'3 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	172,500	125,000	347,500

Earnings_Per_Common_Share_EPS_1

Earnings Per Common Share (EPS) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share, Basic and Diluted [Abstract]	'	'	'	'
Net Income, Basic EPS	$7,764	$5,607	$14,303	$10,030
Shares, Basic EPS	43,229,000	42,596,000	43,053,000	42,560,000
Basic (in dollars per share)	$0.18	$0.13	$0.33	$0.24
Effect of dilutive stock options and warrants	169,000	276,000	262,000	233,000
Net Income, Diluted EPS	$7,764	$5,607	$14,303	$10,030
Shares, Diluted EPS	43,398,000	42,872,000	43,315,000	42,793,000
Diluted (in dollars per share)	$0.18	$0.13	$0.33	$0.23
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,173,000	1,857,000	1,427,000	2,125,000

Acquisitions_Purchase_Price_Al

Acquisitions - Purchase Price Allocation (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Oct. 04, 2013	Oct. 04, 2013	Oct. 04, 2013	Oct. 04, 2013	Oct. 04, 2013	Oct. 04, 2013	Oct. 04, 2013	Oct. 04, 2013
In Thousands, unless otherwise specified			Radial Assist	Datascope	Developed technology	Developed technology	Customer lists	Customer lists	Trademarks	Trademarks
					Radial Assist	Datascope	Radial Assist	Datascope	Radial Assist	Datascope
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'
Inventories	'	'	$16	$478	'	'	'	'	'	'
Intangibles	'	'	'	'	1,520	18,200	20	390	40	320
Goodwill	184,505	184,505	904	8,112	'	'	'	'	'	'
Total assets acquired	'	'	$2,500	$27,500	'	'	'	'	'	'

Acquisitions_Pro_Forma_Consoli

Acquisitions - Pro Forma Consolidated Results (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Business Combinations [Abstract]	'	'	'	'
Revenues	$128,808	$115,210	$376,909	$329,033
Sales, Pro Forma	'	116,971	'	334,317
Net income	7,764	5,607	14,303	10,030
Net income, Pro Forma	'	$5,788	'	$10,572
EARNINGS PER COMMON SHARE:	'	'	'	'
Earnings per common share: basic (in dollars per share)	$0.18	$0.13	$0.33	$0.24
Earnings per common share: basic, Pro Forma (in dollars per share)	'	$0.14	'	$0.25
Earnings per common share: diluted (in dollars per share)	$0.18	$0.13	$0.33	$0.23
Earnings per common share: diluted, Pro Forma (in dollars per share)	'	$0.14	'	$0.25

Acquisitions_Narrative_Details

Acquisitions - Narrative (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

Jul. 15, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Aug. 08, 2014

Sep. 30, 2014

Dec. 31, 2012

8-May-14

Oct. 04, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 08, 2014

Sep. 30, 2014

Aug. 08, 2014

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jul. 15, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Oct. 04, 2013

GMedix [Member]

GMedix [Member]

GMedix [Member]

Datascope

Datascope

Radial Assist

Distribution Rights [Member]

Distribution Rights [Member]

Developed technology

Developed technology

Developed technology

Developed technology

License agreements

Customer Lists

Customer Lists

Trademarks

Trademarks

Wells Fargo Credit Agreement

Datascope

Radial Assist

Datascope

Radial Assist

Datascope

Radial Assist

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to acquire intangible assets

'

$2,000,000

$1,368,000

$1,143,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional consideration due if certain milestone are met

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible asset

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

1,800,000

'

'

'

'

'

'

'

'

Useful life

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'10 years

'

'10 years

'10 years

'10 years

'6 years

'6 years

'15 years

'15 years

'

Payments to Acquire Investments

752,000

'

'

'

'

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost Method Investments, Interest Acquired, Number of Units

'

'

'

'

'

'

'

737,628

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost Method Investments, Ownership Percentage

'

'

'

'

'

'

'

19.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Businesses, Net of Cash Acquired

'

'

4,202,000

1,000,000

'

1,450,000

350,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to acquire businesses

'

'

'

'

'

'

'

'

27,500,000

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Income before tax

'

'

'

'

'

'

'

'

'

1,600,000

191,000

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average useful life

'

'

'

'

'

'

'

'

'

'10 years

'10 years 0 months 27 days

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt issuance costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$798,000

Segment_Reporting_Sales_by_Bus

Segment Reporting - Sales by Business Segment (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	$128,808	$115,210	$376,909	$329,033
Operating Income (Loss)	12,076	8,391	25,949	16,928
Cardiovascular Segment	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	124,191	110,859	363,767	316,566
Operating Income (Loss)	11,520	7,753	25,216	16,031
Endoscopy Segment	'	'	'	'
Revenue from External Customer [Line Items]	'	'	'	'
Revenues	4,617	4,351	13,142	12,467
Operating Income (Loss)	$556	$638	$733	$897

Income_Taxes_Narrative_Details

Income Taxes - Narrative (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Effective tax rate	24.30%	12.90%	25.60%	14.00%

Longterm_Debt_Narrative_Detail

Long-term Debt - Narrative (Details) (USD $)

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Dec. 19, 2012

Sep. 30, 2014

Dec. 19, 2012

Sep. 30, 2014

Dec. 19, 2012

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Oct. 04, 2013

Sep. 30, 2010

Dec. 19, 2012

Sep. 30, 2014

Dec. 19, 2012

Sep. 30, 2014

Credit Agreement

Credit Agreement

Base Rate

Base Rate

London Interbank Offered Rate (LIBOR) Market Index Rate

London Interbank Offered Rate (LIBOR) Market Index Rate

London Interbank Offered Rate (LIBOR)

London Interbank Offered Rate (LIBOR)

Federal Funds Rate

Variable Rate 1

Variable Rate 1

Variable Rate 2

Variable Rate 2

Revolving Credit Facility

Revolving Credit Facility

Term Loan

Bridge Loan

Bridge Loan

Bridge Loan

quarter

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Wells Fargo

Credit Agreement

Base Rate

London Interbank Offered Rate (LIBOR) Market Index Rate

London Interbank Offered Rate (LIBOR) Market Index Rate

Credit Agreement

Credit Agreement

Credit Agreement

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Amount Outstanding

$240,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

215,000,000

125,000,000

100,000,000

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

1.00%

0.25%

2.00%

1.25%

2.00%

1.25%

'

'

'

'

'

'

'

'

'

2.00%

1.25%

Debt Instrument, Basis Spread on Base Rate

'

'

'

'

'

'

'

0.01

0.005

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Current Quarter, Maximum

4.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter One, Maximum

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter Two, Maximum

3.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter Three, Maximum

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter Four, Maximum

3.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Year Two, Maximum

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Year Three, Maximum

2.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Year Four, Maximum

2.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated EBITDA to Fixed Charges Ratio, Number of Consecutive Quarters

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated EBITDA to Fixed Charges Ratio, Minimum

1.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Net Income, Maximum

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Facility Capital Expenditures, Next Twelve Months, Maximum

30,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Minimum

'

'

'

2.25

'

2.25

'

2.25

'

'

'

'

'

'

'

'

2.25

'

'

Line of Credit Facility, Remaining Borrowing Capacity

19,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate

3.23%

4.23%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Percentage Bearing Fixed Interest, Amount

141,300,000

145,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate

'

'

'

'

'

'

'

'

'

2.41%

3.42%

2.49%

3.50%

'

'

'

'

'

'

Long-term Debt, Percentage Bearing Variable Interest, Amount

'

'

'

'

'

'

'

'

'

$39,700,000

$101,500,000

$59,484,000

$2,354,000

'

'

'

'

'

'

Longterm_Debt_Principal_Balanc

Long-term Debt - Principal Balances under Long-term Debt (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Line of Credit Facility [Line Items]	'	'
Total long-term debt	$240,484	$248,854
Less current portion	10,000	10,000
Long-term portion	230,484	238,854
Term Loan	'	'
Line of Credit Facility [Line Items]	'	'
Total long-term debt	85,000	92,500
Revolving Credit Facility	'	'
Line of Credit Facility [Line Items]	'	'
Total long-term debt	$155,484	$156,354

Longterm_Debt_Future_Minimum_P

Long-term Debt - Future Minimum Payments on Long-term Debt (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
2014	$2,500	'
2015	10,000	'
2016	10,000	'
2017	217,984	'
Total long-term debt	$240,484	$248,854

Derivatives_Interest_Rate_Swap

Derivatives - Interest Rate Swap (Details) (USD $)	Sep. 30, 2014	Dec. 19, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'	'
Notional Amount of Interest Rate Cash Flow Hedge Derivatives	'	$150,000,000
Derivative, Fixed Interest Rate	'	0.98%
Derivative, Quarterly Percentage Reduction of Notional Amount by Minimum Principal Payment	'	50.00%
Interest Rate Cash Flow Hedge Asset at Fair Value	1,137,000	'
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Tax	$442,000	'

Derivatives_Foreign_Currency_F

Derivatives - Foreign Currency Forward Contracts (Details)	0 Months Ended
In Thousands, unless otherwise specified	30-May-14	30-May-14
	30 Day Forward Contract EURO	30 Day Forward Contract GBP
	EUR (€)	GBP (£)
Derivatives, Fair Value [Line Items]	'	'
Derivative, Notional Amount	€ 1,218	£ 741
Forward Contract Term	'30 days	'30 days

Fair_Value_Measurements_Financ

Fair Value Measurements - Financial Assets and (Liabilities) Carried at Fair Value (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest Rate Cash Flow Hedge Asset at Fair Value	$1,137		'
Fair Value, Measurements, Recurring | Estimate of Fair Value, Fair Value Disclosure	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest Rate Cash Flow Hedge Asset at Fair Value	1,137	[1]	1,203
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest rate swap	0	[1]	0
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest Rate Cash Flow Hedge Asset at Fair Value	1,137	[1]	1,203
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest rate swap	$0	[1]	$0
[1]	The fair value of the interest rate swap is determined based on forward yield curves.

Fair_Value_Measurements_Liabil

Fair Value Measurements - Liability Measured on Recurring Basis, Unobservable Input Reconciliation (Details) (Contingent Consideration, USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Contingent Consideration	'	'	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'	'	'
Beginning balance	$2,507	$6,692	$2,526	$6,697
Fair value adjustments recorded to expense during the period	-773	-4,108	-754	-4,075
Contingent payments made	-17	-22	-55	-60
Ending balance	$1,717	$2,562	$1,717	$2,562

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value Inputs, Liabilities, Quantitative Information (Details) (Contingent Consideration, USD $)

Sep. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

In Thousands, unless otherwise specified

Income Approach Valuation Technique

Minimum

Maximum

Revenue-based Payments

Revenue-based Payments

Other Payments

Other Payments

Fair Value, Inputs, Level 3

Income Approach Valuation Technique

Income Approach Valuation Technique

Income Approach Valuation Technique

Income Approach Valuation Technique

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate

'

'

'

'

'

'

5.00%

1.00%

14.00%

'

'

'

'

Contingent consideration liability

$1,717

$2,507

$2,526

$2,562

$6,692

$6,697

'

'

'

$1,462

'

$255

'

Probability of milestone payment

'

'

'

'

'

'

'

'

'

'

90.00%

'

100.00%

Fair_Value_Measurements_Narrat

Fair Value Measurements - Narrative (Details) (USD $)	3 Months Ended		9 Months Ended						3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014
					Other Long-term Obligations	Other Long-term Obligations	Accrued Liabilities	Accrued Liabilities	Ostial Solutions, LLC [Member]	Ostial Solutions, LLC [Member]
										Developed technology
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'	'	'	'	'	'
Other Asset Impairment Charges	$1,241,000	$8,100,000	$1,360,000	$8,200,000	'	'	'	'	'	'
Contingent consideration liability	'	'	'	'	1,400,000	2,300,000	'	'	'	'
Contingent consideration liability	'	'	'	'	'	'	365,000	274,000	'	'
Fair value reductions to contingent consideration liability	874,000	3,800,000	'	'	'	'	'	'	'	'
Intangible assets impairment charge	1,102,000	8,089,000	1,102,000	8,089,000	'	'	'	'	1,100,000	'
Fair value of intangible assets	'	'	'	'	'	'	'	'	'	$447,000

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Other Intangible Assets (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	$50,706	$47,805
Accumulated Amortization	-21,361	-18,870
Net Carrying Amount	29,345	28,935
Patents	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	9,921	9,302
Accumulated Amortization	-2,104	-2,374
Net Carrying Amount	7,817	6,928
Distribution agreements	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	5,376	5,176
Accumulated Amortization	-2,139	-1,780
Net Carrying Amount	3,237	3,396
License agreements and trademarks	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	6,327	3,783
Accumulated Amortization	-1,664	-1,249
Net Carrying Amount	4,663	2,534
Trademarks	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	7,313	7,622
Accumulated Amortization	-1,961	-1,844
Net Carrying Amount	5,352	5,778
Non-compete agreements	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	1,029	1,029
Accumulated Amortization	-577	-399
Net Carrying Amount	452	630
Customer lists	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	20,473	20,626
Accumulated Amortization	-12,649	-10,957
Net Carrying Amount	7,824	9,669
Royalty agreements	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	267	267
Accumulated Amortization	-267	-267
Net Carrying Amount	$0	$0

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Future Amortization Expense (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'
2014	$3,821
2015	15,031
2016	14,303
2017	13,898
2018	$13,369

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Narrative (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Aggregate amortization expense	$3,800,000	$3,400,000	$11,200,000	$10,400,000
Intangible assets impairment charge	1,102,000	8,089,000	1,102,000	8,089,000
Fair value reductions to contingent consideration liability	$874,000	$3,800,000	'	'